What Fueled The Previous Growth In The Predictive And Presymptomatic Testing Market?
The predictive and presymptomatic testing market has seen considerable growth due to a variety of factors.
• In recent years, the market size for predictive and presymptomatic testing has seen swift expansion. It's projected to increase from $5.24 billion in 2024 to $5.78 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.3%.
This growth during the historical period can be connected with a rise in occurrences of genetic disorders, a growing demand for initial diagnosis of lingering diseases, an increase in cases of cancer, a rise in the uptake of personalized medicine, and a larger availability of direct-to-consumer genetic tests.
How Does the Forecast Look for the Predictive And Presymptomatic Testing Market?
The predictive and presymptomatic testing market is expected to maintain its strong growth trajectory in upcoming years.
• The sector for predictive and presymptomatic testing is projected to undergo swift expansion in the upcoming years, with its market size ballooning up to $8.47 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 10.1%.
This growth throughout the forecasted period can be credited to several factors including an escalating demand for early detection of diseases, increasing capital directed towards biotechnology and genomics, a rising preference for non-invasive testing approaches, an augmenting geriatric populace, and expansion in precision medicine efforts. Prominent trends for the forecasted period encompass the incorporation of personalized medicine, the use of home testing kits, the merger of genomics and big data, advancements in next generation sequencing (NGS) technologies, and the application of predictive testing in the process of drug development.
What Are The Leading Drivers Of Growth In The Predictive And Presymptomatic Testing Market?
The escalating occurrence of genetic abnormalities is anticipated to spur the expansion of the predictive and presymptomatic testing market in the future. Genetic abnormalities are ailments resulting from irregularities in deoxyribonucleic acid (DNA), such as gene mutations and chromosomal alterations, with instances like cystic fibrosis and Down syndrome. This rise in genetic abnormalities can be attributed to factors such as advancing maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing is key in decreasing the incidence of genetic disorders by pinpointing individuals at risk prior to symptoms appearing. This preemptive strategy paves the way for early interventions or changes in lifestyle that can contribute to the prevention or lessening of these conditions. For example, according to the American Society of Gene and Cell Therapy, a non-profit medical and scientific organization based in the US, there was a 10% quarterly increase in Phase III gene therapy clinical trials in June 2023, the first increase since the third quarter of 2022. Consequently, the escalating occurrence of genetic abnormalities is fueling the growth of the predictive and presymptomatic testing market.
How Are The Segments Defined Within The Global Predictive And Presymptomatic Testing Market?
The predictive and presymptomatic testing market covered in this report is segmented –
1) By Test Type: Predictive Testing, Presymptomatic Testing
2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications
3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders, Prenatal Predictive Testing, Pharmacogenomic Testing
2) By Presymptomatic Testing: Huntington’s Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer’s Disease Testing, Carrier Screening for Genetic Conditions, Testing for Early Signs of Neurodegenerative Diseases, Presymptomatic Genetic Testing for Familial Diseases
Pre-Book The Predictive And Presymptomatic Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Predictive And Presymptomatic Testing Market?
Leading companies in the predictive and presymptomatic testing market are pioneering innovative examinations such as multigene testing. This is a breakthrough medical diagnostic technique that simultaneously scrutinizes numerous genes to pinpoint potential health threats and facilitates early intervention methods. Multigene testing can identify genetic mutations or anomalies tied with specific illnesses or conditions, assisting in custom-built medicine and targeted treatment blueprints. For instance, in July 2022, Genetic Technologies Limited, a biotech research firm based in Australia, formed a collaboration with Siles Health, a women's healthcare facility based in Australia. They launched the geneType Multi-Risk Test, designed to offer comprehensive risk evaluations for patients. This test serves as a thorough genetic assessment instrument that estimates a patient's risk for various severe diseases such as breast cancer, colorectal cancer, and type 2 diabetes. By examining both inherited and random genetic elements, the test aims to guide personalized healthcare plans and encourage early interventions.
Who Are the Key Players In The Predictive And Presymptomatic Testing Market?
Major companies operating in the predictive and presymptomatic testing market are:
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Mayo Clinic
• Quest Diagnostics Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Peter MacCallum Cancer Centre
• Myriad Genetics Inc.
• SomaLogic Inc.
• Siteman Cancer Center
• Dante Labs S.R.L.
• Mapmygenome
• Manipal Health Enterprises
• Gene Vision
• Reliance Diagnostic
• GenepoweRx
• Personal Genomics
• Apollo Hospitals Enterprise Limited
• Cardio Diagnostics Inc.
What Is The Most Dominant Region In The Predictive And Presymptomatic Testing Market?
North America was the largest region in the predictive and presymptomatic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
